[4] SUSTAIN-6 (semaglutide) : In 3,297 high-risk patients with type 2 diabetes, once-weekly semaglutide reduced major cardiovascular events by 26% and stroke by 39% over two years
It is a synthetic peptide that acts as an analog of -melanocyte stimulating hormone (-MSH)
Semaglutide slows stomach emptying , helps people feel full sooner, supports healthy insulin release, and reduces appetite
Theres a myth that natural equals unsafe, and some skeptics worry about the use of plant-based ingredients without understanding their long-term effects
Moreover, deficiency of autophagy regulatory factors such as autophagy-related 4C cysteine peptidase (ATG4C) is more likely to cause cancer (50)
The following milestones mark important progress in the consolidated federal litigation: Increased evidentiary standards for gastroparesis claims: Courts require plaintiffs alleging gastroparesis to support claims with objective gastric-emptying tests rather than symptoms alone, raising the bar for admissible medical evidence Daubert hearings on expert testimony: May 2025 hearings will determine whether plaintiffs medical experts can testify about causation potentially decisive rulings that could strengthen or weaken thousands of claims Short-form complaint process adoption: MDL implemented streamlined filing procedures to manage the influx of new cases efficiently while maintaining procedural fairness Monthly status conferences throughout 2025: Regular court meetings ensure ongoing case management and coordination as parties work through challenging scientific and legal issues In September 2025, Judge Marston allowed most plaintiffs claims to proceed after denying defendants motions to dismiss, including accusations that drugmakers failed to warn about gastrointestinal issues and misrepresented safety
